Actionable targets in patients with cisplatin-resistant advanced germ cell tumours

Dr Bagrodia talks to ecancertv at ASCO GU 2016 about actionable targets in patients with cisplatin-resistant advanced germ cell tumours.

Approximately 30% of patients with advanced germ cell tumour will progress after first-line chemotherapy.

Nearly half of these patients will die of progressive germ cell tumours.

Dr Bragrodia describes actionable alterations that may guide treatment selection in a significant proportion of patients with cisplatin-resistant advanced germ cell tumours.

Targeted sequencing of these patients may allow enriched clinical trials in the future with patients whose tumours harbour alterations in the drug target of interest.